Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell…
WATCHLIST NOV 04 2026 Benzinga PreMarket Gainers (% change and volume) $CRIS $DKI $ALIT $WORX $CPSH $STIM $HPAI $FTCI $CHSN Read our Benzinga Review here: https://t.co/DbZGLBN9ND https://t.co/HxXzWZSvzf
Consensus price target: $42.67 (+3744.14% upside from $1.11)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| KAITIN KENNETH I director | Mar 31, 2026 | Purchase | 10,000 | $5.49K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $9.44M | -13.43% | $-7.58M |
| 2024 | $10.91M | +8.83% | $-43.39M |
| 2023 | $10.02M | -1.37% | $-47.41M |
Stock data for CRIS: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics